Boehringer Reflects On Resilience Of Older Therapies

As Early-Stage Oncology Pipeline Advances

 
• By Kevin Grogan
golden eggs
Spiriva, Pradaxa And Trajenta still big-earners for Boehringer

More from Earnings

More from Business